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MHC class II complexes sample intermediate
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The presentation of peptide-MHCII complexes (pMHCIIs) for surveillance by T cells is a
well-known immunological concept in vertebrates, yet the conformational dynamics of
antigen exchange remain elusive. By combining NMR-detected H/D exchange with Markov
modelling analysis of an aggregate of 275 microseconds molecular dynamics simulations,
we reveal that a stable pMHCII spontaneously samples intermediate conformations relevant
for peptide exchange. More specifically, we observe two major peptide exchange pathways:
the kinetic stability of a pMHCII’s ground state defines its propensity for intrinsic peptide
exchange, while the population of a rare, intermediate conformation correlates with the
propensity of the HLA-DM-catalysed pathway. Helix-destabilizing mutants designed based
on our model shift the exchange behaviour towards the HLA-DM-catalysed pathway and
further allow us to conceptualize how allelic variation can shape an individual’s MHC
restricted immune response.
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Antigen-specific recognition of peptide-major histocompat-ibility class II (MHCII) complexes (pMHCIIs) by CD4þT cells represents a key feature of acquired immunity.
Professional antigen-presenting cells express a subset of different
alleles of heterodimeric MHCII proteins on their surface. These
MHCII proteins are capable of binding and presenting both
foreign and self-antigens to potentially activate CD4þ T cells via
cognate T cell receptors as part of the adaptive immune response.
The structural hallmarks of antigen binding by MHCII molecules
are well understood at the phenomenological level: Optimal
occupation of the four main pockets (P1, P4, P6, P9) in the
MHCII-binding groove by peptide side-chains and concomitant
formation of a conserved set of hydrogen bonds mainly between
peptide backbone and MHCII side-chains are necessary and
sufficient to guarantee high-affinity binding of certain epitopes
and their subsequent surveillance by T cells1–3. Initially, the
class II-associated invariant chain peptide (CLIP) occupies the
MHCII-binding groove, but can later be replaced in the
endosomal compartments for higher affinity antigens. Here
under acidic conditions, the exchange reaction can be catalysed
by the non-classical MHCII molecule HLA-DM (DM)4–8. The
propensity to exchange peptides depends on the kinetic stability
of an individual pMHCII, as measured by its intrinsic dissociation
rate. Stable complexes, however, are also prone to DM-mediated
exchange, and it has been postulated that MHCII dynamically
samples alternative conformations9–12, which is a major
prerequisite for DM susceptibility13.
A recently solved pMHCII/DM crystal structure highlights the
extensive conformational changes in the P1 pocket region
required for DM binding of a pMHCII (ref. 14). As yet, details
of the molecular mechanism leading to DM binding and
peptide exchange remain elusive, but its understanding is of
utmost importance for the concepts of immunodominance and
autoimmunity15–19.
Here we show by an integration of structural, biophysical and
theoretical methods, that pMHCIIs spontaneously sample
transient conformations that have secondary structural features
of the DM-stabilized peptide exchange complex. By comparing
the stable wild-type pMHCII to a mutant not relying on DM for
fast exchange, we reveal the existence of two major peptide
exchange pathways, one offering spontaneous release, the other
one relying on DM catalysis. For the catalysed exchange pathway
we reveal a series of spontaneously occurring conformational
changes, which share some, but not all features with the
DM-bound structure, and which potentially promote DM
binding. Which of these pathways predominates and thus how
immune responses are shaped is determined by an individual’s
particular combination of expressed MHCII alleles and available
peptides.
Results
A stable pMHCII shows inherent conformational plasticity. In
order to unravel the impact of conformational plasticity on
peptide exchange, we first characterized a kinetically stable
pMHCII as reference, an HLA-DR1/CLIP complex with the
P1-methionine of the natural placeholder CLIP102–120 substituted
for tryptophan (DR1/CLIP102–120M107W, shortened: DR1/CW).
The expected advantage of choosing this reference is an increased
stability of the pMHCII as the tryptophan side-chain optimally
fills the P1 pocket that dominates the DR1-binding groove,
but cannot be accommodated by P9 and thus prevents peptide
reorientation20. Indeed, the DR1/Cw complex is markedly
more resistant to exchange against a fluorescein-labelled
haemagglutinin (HA)-derived peptide than DR1 loaded
with wild-type CLIP (DR1/C), as detected by an FP-based
peptide-exchange assay (Fig. 1a). A small but significant increase
of the stability of this complex is also reflected by a gain
in midpoint denaturation temperature of approximately 4 !C
(Supplementary Table 1). Additionally, we solved the crystal
structure of DR1/CW at 1.4 Å resolution (Fig. 1b and
Supplementary Table 2), and confirmed that DR1/CW has the
standard canonical fold and that the new tryptophan side-chain is
well accommodated by the P1 pocket.
Previous studies suggested that in order to be amenable for
peptide exchange, a pMHCII must be able to transiently sample
exchange-competent excited conformational states13,14,21–23. In
order to identify secondary structure elements that could undergo
conformational changes in solution, we subjected the DR1/Cw
complex to NMR-detected H/D exchange (HDX) measurements
that report the dynamical exposure of amide protons to the
solvent. HDX protection factors were derived from exponentially-
fitted (EX2 regime) intensity decays of backbone amide signals in
a series of heteronuclear single quantum coherence (HSQC)
spectra (Fig. 1c,d, Supplementary Table 3, Supplementary
Fig. 1a,b). The results reveal that the N-terminal half (region
coloured red in Fig. 1c) of the peptide-binding groove extending
from the P1 to P6 pocket region, including residues aF48-L60
and bK65-Q92, displays strikingly little protection from HDX in
DR1/Cw. Additionally, the indole proton of the highly conserved
aW43, which is needed to flip out of the peptide-binding groove
to form an essential part of the DM interface14, is not protected
from HDX indicating side-chain mobility.
Thus, although the crystal structure displays several hydrogen
bonds in the P1 pocket region of the peptide-binding groove,
this part of the protein appears to represent a rather flexible
sub-module surrounding the N-terminal part of the peptide
(Fig. 1c). This includes the side-chain of aW43 and the adjacent
helical segments of both MHCII chains, thereby covering part of
the main binding site of the exchange catalyst DM (see Fig. 1b for
a sketch of the DM interface).
In order to reveal structural details and transition rates
of the dynamical changes, we conducted extensive all-atom
explicit-solvent molecular dynamics (MD) simulations. Over 160
simulation trajectories adding up to about 90 microseconds of
total simulation time were collected—and thus two to three
orders of magnitude more sampling than in previous simulation
studies9–12—combined and analysed by a Markov state model
(MSM)24,25 using the PyEMMA program26 (see Methods). In
agreement with the HDX results, we found that several secondary
structural elements could undergo spontaneous conformational
fluctuations. Figure 1e shows the three most long-lived metastable
states from our analysis that can interconvert on timescales of a
few microseconds: The most stable ground state MS3WT, and the
less stable excited state MS2WT have an overall structured fold.
Of special interest is MS1WT, a very low-populated state with a
free energy of 19 kJmol" 1 above the ground state that exhibits
unfolding of b1 a-helix residues C79-R93 (Fig. 1e, orange arrow,
and Supplementary Fig. 2), consistent with the HDX results.
Finally, we find that in all three simulated metastable states,
there are spontaneous transitions of aW43 to the outward-flipped
state (Supplementary Fig. 3), consistent with a side-chain
conformation that resembles the DM-bound state14. Moreover,
all three states exhibit flexible termini of the CLIP ligand, which
may be an indication of early steps in a ligand-exchange pathway.
Taken together, the kinetically stable pMHCII DR1/CW
predominantly exists in a ground state, but the N-terminal end
of the peptide-binding groove including the DM-binding site in
the a1-domain as well as the b1-domain a-helix spontaneously
samples low-populated conformations. Despite a well-occupied
P1 pocket the outward-flipping of the aW43 side-chain appears to
be a rare feature of both the ground state and the low-populated
conformations.
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Figure 1 | Conformational plasticity of an intrinsically stable and DM-unresponsive pMHCII complex. (a) Exchange of DR1-bound CLIP (C) or CLIPM107W (CW) for
HA306-318-FITC in the absence or presence of DM at 37 !C as detected by fluorescence polarization, performed as triplicates and representative of three independent
experiments. (b) Crystal structure of DR1/Cw. The DM-binding interface is indicated, DR1 a1/b1 and a2/b2 domains are coloured in light and dark grey, respectively.
The peptide is shown in yellow with its N and C terminus marked. (c) Backbone HDX half-lives observed for DR1/CW plotted onto the structure of DR1/CW, viewed
from the top. ND means not determined. (d) Signal decay due to HDX plotted over time for selected a and b residues in DR1/CW. (e) Kinetic maps of Markov state
models obtained from our in total 90ms molecular dynamics simulations of DR1/CW. Metastable states (MS) are represented as black discs with areas proportional to
the relative stationary weight of an MS. The black arrows in these maps indicate transitions between metastable sates, where the width of each arrow increases with
the corresponding transition rate. Relative free energies and transition rates for the MSs are each presented with a ‘lower-/upper-case’ 1s confidence interval. Each MS
is illustrated by ribbon representations of MHCII (white) and CLIP (magenta) of eight simulated conformations (one opaque, seven transparent viewed from the top
into the binding groove). The a-helix of bA74-R93 is highlighted in orange, and the side-chains of aW43 and bN82/A as sticks and a space fill model, respectively. An
orange arrow highlights the distortion of in the b-chain a-helix (b74-93). The simulated conformations were superimposed using the iterative fit VMD plugin78,80.
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Indication of a rare conformation during peptide exchange.
Interestingly, the flexible N-terminal end of the peptide-binding
groove covers part of the main binding site of the exchange
catalyst DM, spanning a1-chain residues aK39-aL60 (see Fig. 1b
for a sketch of the DM interface). Moreover, a region on the
opposite side of the peptide-binding groove (bV85-V91) has also
been shown to rearrange upon DM binding14. Thus, it appears
likely that enhanced dynamics of the N-terminal end of the
peptide-binding groove are a prerequisite for DM interaction.
Conformational plasticity of the DM-binding site in the a1
domain has already been suggested to represent a prerequisite for
catalysed peptide exchange, and various mutations within this
region have been shown to modulate DM susceptibility13,14,21,27.
In order to unravel the relevance of the observed transient local
unfolding of the b1 domain a-helix for peptide exchange, we
asked for the structural and dynamic impact of a mutation that
further destabilizes that region. We introduced an alanine in
position b82 deleting the two H-bonds between bN82 and the
peptide’s P2 site, which have been shown to contribute
remarkably to pMHCII stability1,3,21. Indeed, DR1-bN82A/CW
is a kinetically destabilized complex that displays a clear reduction
in thermal stability of 19 !C (Supplementary Table 1),
concomitant with a dramatic acceleration of the non-catalysed
(DM-independent) peptide-exchange rate (Fig. 2a). Strikingly,
Surface plasmon resonance (SPR) measurements report that the
binding of the mutant to DM is massively increased, showing a
KD value in the 100 nM range for DR1-bN82A loaded with CW as
well as another high-affinity peptide (HA), while binding of
DR1/CW to DM was hardly detectable (Fig. 2b,c)28. Thus,
DR1-bN82A/CW captures features of a late intermediate of the
peptide-exchange mechanism, as it tightly binds the catalyst
without depending on its action.
In order to elucidate the basis of this phenotype, we solved the
crystal structure of DR1-bN82A/CW. The limited resolution of
3.2 Å (Supplementary Table 2) was conceivably due to the
reduced thermodynamic stability of this complex. Surprisingly,
the DR1-bN82A/CW structure was nearly indistinguishable from
the high resolution DR1/CW structure, with an root-mean-square
deviation (RMSD) value of only 0.432Å (Fig. 2d and
Supplementary Fig. 4a). Also the comparison of B-factor
distributions, normalized to the mean B factor of each chain,
did not reveal gross differences between both structures with
variability found in those regions that also differ between all
HLA-DR1-CLIP structures deposited to date (data not shown).
Moreover, nuclear Overhauser enhancement spectroscopy
(NOESY) spectra of DR1-bN82A/CW in solution did not indicate
structural alterations if compared with the much more stable
DR1/CW complex (Supplementary Fig. 4b–d), and chemical shift
differences between 1H-15N-TROSY-HSQC spectra of both DR1-
bN82A/CW and DR1/CW were restricted to the site of mutation
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Figure 2 | The intermediate state behaviour of DR1-bN82A/CWis not mediated by structural alteration. (a) Exchange of DR1- or DR1-bN82A-bound
CLIPM107W (Cw) for HA306-318-FITC in the absence or presence of DM at 25 !C, performed as triplicates and representative of two independent
experiments. Plotted are the mean values±standard deviation of the change in fluorescence polarization (DFP, calculated by subtracting the detected FP
values of a protein-free reaction [HA-FITC only] from the reaction containing the DR/peptide complexes) over time. (b) SPR-detected binding of DR1/
peptide complexes to immobilized DM. In all, 5mMDR1/peptide complexes (DR1/C [wt CLIP] or DR1/CW CLIPM107W and DR1-bN82A/CW CLIPM107W) are
allowed to bind to the chip, washed with buffer and released by HA-peptide injection. (c) Req-plots for the SPR-detected binding of DM to DR1-bN82A
bound to Cw or HA306-318 at different substrate (DR/peptide) concentrations, with calculated KD values ± standard deviation resulting from two
experiments. (d) Left: Structural alignment of DR1/CW (grey) and DR1-bN82A/CW (red). Right: magnification of the N-terminal-binding groove highlighting
the H-bonds formed between bN82 and the P2 site of the peptide. (e) Box-and-whisker plot of signal-to-noise ratios (S/N) for backbone NH groups of the
individual domains of DR1/CW and DR1-bN82A/CW (a1: assigned residues of 2-85, a2: 86-189, b1: 6-95 and b2: 96-193) showing the significant global
increase in line broadening of the b1 domain in DR1-bN82A/CW relative to the WTcomplex. The box includes the median and the 25th and 75th percentiles,
respectively. The whisker represent 1.5 standard deviations. ***Po0.001, *Po0.05 (t test).
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(Supplementary Fig. 5a,b). Having no indication for major
structural changes in the peptide-bound conformation, we also
ruled out that DR1-bN82A has lost most of the bound peptide
and might behave as an empty MHCII: Spectra of DR1-bN82A/
CW are consistent with a peptide-loaded conformation as they did
not show the massive loss of signals characterizing a destabilized
binding groove in peptide-free DR1 (exemplified in
Supplementary Fig. 5c), and the presence of peptide-loaded
DR1-bN82A was further confirmed by peptide dissociation
experiments (Supplementary Fig. 5d–f).
Thus, even in the context of an optimal P1 anchor residue, a
mutation in the b1 domain a-helix leads to a kinetically instable
complex (DR1-bN82A/CW) that tightly binds DM. This
biochemical phenotype is not explained by the ground-state
structure as detectable by crystallography and NMR.
HLA-DR1 excited states rationalize catalysed exchange.
As the biochemical phenotype of DR1-bN82A/CW could not be
explained by its ground-state structure, we wondered whether its
structural ensemble comprises excited metastable states that
account for accelerated peptide-exchange and increased DM
binding.
A first indication for a difference in conformational plasticity
between DR1-bN82A/CW and DR1/CW is given by a comparison
of 1H-15N TROSY-HSQC peak intensities: Signal-to-noise levels
of the DR1-bN82A/CW b1 domain are reduced to 48% as
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Figure 3 | DR1-bN82A/CW transiently features DM-susceptible conformations. (a) DR1-bN82A/CW backbone NH HDX rates significantly enhanced
(red) or reduced (blue) as compared with DR1/CW are highlighted in the DR1/CW crystal structure, with magnification of two different regions.
(b,c) Comparison of the change in S/N between DR1/CW and DR1-bN82A/CW upon HDX for the NH groups of b85Val (b), located in region I, and a22Phe
(c) located in region II . (d) Kinetic maps of our MD simulations of DR1-bN82A/CW with metastable sates, transition rates and conformations represented
as in Fig. 1g. Coloured arrows highlight characteristic conformational changes, that is, the a-helix distortion of b74-93 (orange) the side-chain flip of aTrp43
(green), and partial dissociation of CLIP (magenta).
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compared with DR1/Cw (Fig. 2e), suggesting a higher plasticity of
DR1-bN82A/CW compared with DR1/CW. This effect remained
significant at lower temperatures (Supplementary Fig. 6).
In order to give a detailed account of these altered dynamics
we performed HDX measurements as described above and
observed greatly amplified internal dynamics in DR1-bN82A/CW
compared with DR1/CW (Fig. 3a–c and Supplementary Table 4).
In particular, the b1 domain a-helix residue bR80 and region
bG84-R93 in the vicinity of the mutation were destabilized
(Fig. 3a, region I).
The impact of these increased internal dynamics on the
conformational space of DR1-bN82A/CW was again analysed
using a total of 90 microseconds of explicit-solvent MD
simulations and a subsequent Markov model analysis (Fig. 3d).
These simulation data show a qualitatively similar picture as for
DR1/CW, but with shifted populations and enhanced structural
flexibility. The ground-state MS3bN82A has a mostly stable fold
similar to DR1/CW, in agreement with our X-ray structures,
NOESY measurements and chemical shift perturbation data.
Again, two excited metastable states with low populations are
found, one with a well-defined fold (MS2bN82A), and one where
the b1 domain a-helix is largely unfolded at residues bQ70-R93
(MS1bN82A, Fig. 3d, orange arrow and Supplementary Fig. 2). The
a-helix unfolding is more pronounced than the partial helix
breaks observed in DR1/CW. However, the most striking effect is
the relative stabilization of MS1bN82A over MS1WT by 9 kJmol" 1
(from 19 kJmol" 1 to 10 kJmol" 1—compare Fig. 3d and 1e).
While it is still a low-populated metastable state with a population
fraction of about 1.6% and has thus escaped characterization by
X-ray and NMR measurements, its population is now increased
by a factor of 28.
Several features of this excited metastable state suggest that
MS1bN82A represents an intermediate state along the peptide
exchange pathway that can be spontaneously sampled in
timescales of about 50–100microseconds: The b1 domain
a-helix conformation in MS1bN82A is in good agreement with
the partially unfolded helix in the DR1/DM complex structure14.
Additionally, the optimal arrangement of the DM-binding site
goes along with an alignment of a-chain b-strands s2 and s3
(Fig. 3a, region II) leading to novel interstrand H-bonds in DM-
bound structures14,29. The increased protection of the
a22F amide observed in HDX experiments of DR1-bN82A/CW
(Fig. 3a,c) is in agreement with an on average more
proximal orientation of the two strands in the mutant. An
increased protection of the adjacent potential H-bond partners
a20G/a36M is not observed, indicating that a full line up of s2
and s3 strands, as seen in the DM/DR1 crystal structure, might
rather occur by an induced-fit mechanism. Instead, increased
protection of a18Q and a19S amide protons additionally indicate
stabilized H-bonds between strands s3 and s4 in DR1-bN82A/CW
and our simulation results indicate a stabilization of the helical
residues aE55-Y79 on top of these b-strands in MS1bN82A as
compared with MS3WT (Supplementary Fig. 7). Overall, however,
the entire region around the N terminus of the peptide displays a
notable increase in mobility (Supplementary Fig. 7). This
increased mobility likely facilitates the conformational change
of the aW43 side-chain to flip outward and thus to participate in
the DM-binding interface, as seen in the DR1/DM crystal
structure14. As a43W He chemical shift differences between
wild-type and mutant pMHCII are relatively small in 1H-15N
TROSY-HSQC spectra (Supplementary Figs 4e and 5b), it has to
be concluded that the flipped-in orientation of the a43W side-
chain is still dominant in DR1-bN82A/CW. This is confirmed by
our MD simulation results, however, we find the probability of
being in a flipped-out state has more than doubled in the DR1-
bN82A/CW mutant compared with DR1/CW (that is, from
0.063±0.003 to 0.16±0.02) (Supplementary Fig. 3). In order to
account for this population increase, MS1bN82A and MS3bN82A
are represented by conformers which show the low-populated
flipped-out a43W side-chain conformation in Fig. 3d (green
arrows).
Taken together, the bN82A mutation destabilizes the b1
domain a-helix fold, which contributes to an overall increase of
the mobility in the entire region surrounding the peptide N
terminus. This destabilization shifts the conformational ensemble
towards the low-populated state that shares features of the
DM-bound conformation14 and thus rationalizes the phenotype of
DR1-bN82A/CW in the DM-catalysed peptide exchange pathway.
Non-catalysed peptide exchange pathway. A key feature of
DR1-bN82A/CW is its high and DM-independent peptide-
exchange rate (Fig. 2a), which cannot be explained by the
simulated excited state MS1bN82A but MS3bN82A:
Compared with DR1/CW, in DR1-bN82A/CW we observe the
peptide’s residues S105, K106, R108-A110, P112 and A117 to
have a significantly lower contact frequency to any DR1 residue
(magenta arrows in Fig. 3d, Supplementary Fig. 8a). This is
associated with a significantly higher frequency of most of
these residues (S105-R108, A110) to interact with water
(Supplementary Fig. 8b). Interestingly, most of these partial
CLIP dissociation events occur more often in MS3bN82A than in
MS1bN82A (Fig. 3d, Supplementary Fig. 8a).
Thus, our hypothesis is that two major distinct pathways for
peptide exchange are likely to exist in parallel: while the kinetic
stability of the ground state defines the propensity of an
individual pMHCII for uncatalysed peptide exchange, the
population of rare conformations determines DM susceptibility.
Validations of the model of two major exchange pathways. As
shown above, the equilibrium between the two peptide-exchange
pathways exhibiting different DM responsiveness can be shifted
by a single bN82A point mutation at the P2 site. In both our HDX
measurements and MSM analyses of MD simulations (Fig. 3 and
Supplementary Fig. 7), a characterizing feature of this shift is
the unfolding of the MHCII b1 domain a-helix at residues
bQ70-R93. The bN82A mutation, however, does not only
modulate the b1 domain a-helix stability but also markedly
affects peptide dissociation by the removal of two H-bonds.
Hypothesizing two independent exchange pathways, we
anticipate that destabilizing the b1 domain a-helix without
touching the H-bond network between MHCII and peptide
should be sufficient to shift the conformational equilibrium
towards the DM-susceptible state, while helix-stabilization should
not enhance DM binding. In order to test this hypothesis, we
introduced one or two helix-destabilizing proline residues into
the b1 domain a-helix of the wild-type DR1 molecule at positions
pointing away from the binding groove (DR1-bE87P and
DR1-bG84PbE87P) and additionally aimed at stabilizing the
helix by replacing the same residues by leucine, which has a
higher propensity for helix formation due to hydrophobic
contacts (DR1-bG84LbE87L) (Fig. 4a).
SPR measurements show that introduction of one proline
(DR1-bE87P/CW) or two (DR1-bG84PbE87P/CW) leads to com-
plexes with gradually increased binding to DM, whereas
DR1-bG84LbE87L/CW shows a similarly negligible response
to DM as DR1/CW (Fig. 4b). Strikingly, DR1-bE87P/CW’s non-
catalysed peptide exchange is slightly increased as compared with
DR1/CW, but clearly can be enhanced overproportionally by the
addition of DM. For DR1-bG84PbE87P/CW, the non-catalysed
peptide exchange is strongly enhanced but can be further
accelerated upon addition of DM (Fig. 4c–f). In contrast to that,
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DR1-bG84LbE87L/CW shows slightly increased intrinsic peptide
exchange rates but DM does only improve exchange to a level
comparable to DR1/CW. Thus, a successive destabilization of the
b1 domain a-helix by the introduction of proline, especially when
placed at position 87, shifts the conformational equilibrium
from the DR1/CW situation towards a more DM-susceptible
conformation. To the contrary, the introduction of helix-
stabilizing leucine residues does not significantly improve DM
susceptibility.
To validate our model based on previous experimental design we
capitalized on the mutant DR1-aT41A, that has been described to
enhance DM binding and DM-dependent exchange rates without
accelerating non-catalysed peptide dissociation of a high affinity
peptide27. According to our model, this phenotype would be
consistent with a stabilization of the DM-susceptible MS1 states.
We tested this hypothesis with an aggregated total of
95microseconds of explicit-solvent MD simulations and a
subsequent Markov model analysis of DR1-aT41A/CW. Indeed,
we observe a clear destabilization of the same region of the b1
domain a-helix in MS1aT41A and MS2aT41A as observed in
MS1bN82A and MS2bN82A (Fig. 4g, orange arrow, Supplementary
Figs 2 and 7), although the mutation is introduced on the opposite
side of the peptide-binding groove. Despite the mutation’s direct
vicinity to the a43W side-chain, flipped-out conformations are
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Figure 4 | DM-susceptibility is associated with b1 domain a-helix unfolding. (a) Shown is the structure of DR1/CW with the magnified b1domain a-helix.
Two residues (b84G and b87E) that point away from the binding pocket were chosen to either destabilize (by substitution for proline) or stabilize
(by substitution for leucine) the b1 domain a-helix. Additionally, a mutation (DR1-aT41A) on the opposite site of the binding groove previously described
to influence DM susceptibility27 was analysed by simulation. (b) Binding of streptavidin-immobilized biotinylated DM to different DR1/peptide
complexes. Measurements were performed as described in Fig. 2b and are representative of at least three experiments. (c–f) Exchange of DR1-bound CW
for HA306-318-FITC in dependence of DM as detected by fluorescence polarization. Experiments were performed as triplicates and are representative of at
least two independent experiments. Plotted are the mean values±standard deviation of DFP over time. (g) Kinetic Maps of MD simulations of DR1-aT41A/
CW with metastable sates, transition rates and conformations represented as in Figs 1e and 3d.
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similarly frequent in MS1aT41A and MS3aT41A as in MS1bN82A and
MS3bN82A, respectively (Fig. 4g, green arrows, Supplementary
Fig. 3). Moreover, the burial of the CLIP peptide side-chains in
DR1-aT41A/CW is similar to DR1/CW, and thus the peptide is
more tightly bound than in MS3bN82A (Supplementary Fig. 8a).
However, residue P-1 shows more frequent solvent encounters in
MS3aT41A (Supplementary Fig. 8b), thus arguing for flexibility to
increase at the very N terminus of the peptide. All these
observations go along with an even more pronounced
stabilization of MS1aT41A over MS1WT by 14kJmol" 1
(compared with 9 kJmol" 1 for MS1bN82A, see Supplementary
Fig. 7), and provide a possible explanation for why in clear contrast
to the bN82A mutation, aT41A does not significantly enhance non-
catalysed exchange rates of a high affinity peptide27.
Thus, consistent with our model, the equilibrium between
non-catalysed and DM-catalysed peptide exchange pathway can
be shifted towards the latter by mutations that either directly
target the stability of the b1 domain a-helix at residue b87
without removing H-bonds between MHCII and peptide, or by a
mutation of a residue at the opposite side of the binding groove
that is part of the DM interface.
Discussion
Conformational plasticity has long been suspected to lie
at the heart of recapitulating antigen exchange at the molecular
level13,21,27,30–33. Comparing the wealth of solved MHCII-peptide
structures hinted at structural variability that might well extend
beyond the ground-state structures seen so far18,19,22. Two
landmark studies by Pos et al.14 and Guce et al.29 unambiguously
proved the MHCII fold to be prone to large structural
rearrangements when complexes of either MHCII/DM or
DM/DO form. The timescale and order of these transitions as
well as their relevance for either catalysed or uncatalysed peptide
exchange remained enigmatic.
Here we combined NMR and computational MD approaches
to compare the conformational plasticity of a stable pMHCII
(DR1/Cw) that is characterized by low affinity for DM, but exerts
DM-dependent peptide exchange, with the kinetically destabilized
mutant DR1-bN82A/Cw. This mutant, in contrast, showed strong
DM-binding albeit with DM-independent peptide exchange.
Based on aggregate results we are now able to propose a detailed
mechanistic model of MHCII peptide exchange (Fig. 5).
The proposed pathways were rationalized by the comparison of
model sub-states to the DM/DR complex (Supplementary Fig. 9)
and validated by the analysis of further mutations (bE87P,
bG84PbE87P, bG84LbE87L and aT41A):
The propensity for intrinsic, uncatalysed peptide exchange is
determined by the kinetic stability of a pMHCII’s ground state
(Fig. 5a, Supplementary Fig. 9A, Supplementary Movie 1), which
rarely samples slightly higher energy states that are characterized
by flipping-out of the a43W side-chain and/or a destabilized
b79-93 helix (MS1WT in Fig. 1e and Supplementary Fig. 2).
Destabilizing mutations such as bN82A or bG84PbE87P can lead
to a ground state that is clearly more prone to intrinsic peptide
exchange than in case of the stable complex DR1/Cw.
The catalysed peptide exchange pathway, however, occurs from
the MHCII ground-state structure (Fig. 5a) via multi-step
transitions (Fig. 5b,b’, Supplementary Movie (1,2,3)) towards an
energetically excited intermediate (Fig. 5c) that exhibits features
of a DM/DR complex14 (Fig. 5d) with the least number of
significant polar interaction differences with respect to the DR1/
DM crystal structure among all the simulated metastable states
(Supplementary Fig. 9). Thus, the propensity for
DM-catalysed peptide exchange depends on the sampling of a
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Figure 5 | Thermodynamic and kinetic models for catalysed and non-catalysed MHCII-peptide exchange. Along these modelled pathways with
sketched free energy surfaces, representative conformations are shown of MHCII (white ribbons, top view into the binding groove), CLIP (magenta),
antigen (green, sketched) and DM (blue ribbons). In a, b, b’, c, f, we present simulated conformations of MS3WT, MS1bN82A, MS3bN82A, MS1bN82A and
MS3bN82A, respectively, d and e, crystal structures with PDB IDs 4FQX and 1DLH, respectively. In MHCII, helical residues of aR44-E55 and bA74-R93 are
highlighted in red and orange, respectively, and the aW43 side-chain is highlighted in green. The dashed ellipses point out key conformational events along
each peptide exchange pathway.
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low-populated state where the bC79-R93 a-helix partially unfolds
and the a43W side-chain is in the flipped-out conformation
(Fig. 5c, Supplementary Fig. 9c). The resulting transient states
that already carry features of the DM-bound conformation
are spontaneously sampled on timescales of about a hundred
microseconds. Mutations can shift the conformational
equilibrium towards higher DM affinity, as observed for
DR1-bN82A/Cw and DR1-aT41A/Cw, in which the excited
metastable state MS1bN82A and MS1aT41A is 28-fold and
200-fold, respectively, higher populated than in DR1/CW. DM
would then select for conformations with unfolded bC79-R93,
a flipped-out a43W and a flexible peptide N terminus (Fig. 5d,
Supplementary Fig. 9d).
Interestingly, in the DM-bound14 form, the DR1 b-helix is still
destabilized as evidenced by the distortion of bE87 away from the
helical conformation. Two critical intra-helical hydrogen bonds
provided by this residue are not seen in the DM-bound DR1 and
when introducing a proline at this position the NH-based
hydrogen bond to bY83(CO) is disrupted and nicely explains the
increased DM susceptibility of this mutant in the framework of
our model (Fig. 4). The aR44-E55 helix that is observed in the
DR/DM complex14 (Fig. 5d, Supplementary Fig. 9d), is assumed
to fold as part of an induced fit, as we do not detect
its spontaneous formation, neither experimentally nor in our
simulations. Finally, upon DM-binding, peptide exchange occurs
and DM dissociates (Fig. 5e, Supplementary Fig. 9e).
We postulate that the equilibrium between the non-catalysed
as well as the DM-catalysed exchange pathways can be skewed as
a result of various modifications as implied by the investigated
mutations on both sides of the binding groove. As peptide affinity
influences kinetic stability of pMHCII complexes, binding
groove pocket occupation will also affect the populations
of the conformational states. In this study, we used a CLIP
peptide variant modified to increase the stability of the pMHCII
complex in order to derive features independent of the effect of
non-optimal pocket occupation. In case of wild-type CLIP, which
has a sub-optimal P1 pocket packing, we expect based on its
reduced kinetic stability an increase of both non-catalysed
and DM-catalysed peptide exchange. An empty P1 pocket13,
however, does not appear to be the only prerequisite for
the formation of DM-susceptible conformations, as indicated
by the aT41A mutation27 (Fig. 4g). Thus, in the context of a
low-affinity peptide we would anticipate that destabilizing
mutations or polymorphisms have an additive effect and that
enthalpic and entropic contributions from the entire pMHCII
system determine the DM susceptibility of an individual pMHCII
(refs 27,33).
Our data are in agreement with previous observations that
dynamics in the 310-helical region of the DR a-chain and the
P1 pocket are of great relevance for the peptide-exchange
reaction15,16,21, but we provide evidence that the stability of the
adjacent helical hinge segment in the b-chain a-helix is also
important, as its loss in DR1-bN82A/CW is associated with
enhanced peptide-exchange rates (Figs 1, 3 and 4, Supplementary
Figs 2 and 7, Supplementary Table 4). This is supported by
the observation that the DM/DR crystal structure and
MD simulations of the peptide-free conformation of DR
show structural re-arrangements involving MHCII residues
bV85-V91 and bC79-Y83, respectively10,14. Taking into account
that transient helix unfolding as observed for DR1 b-chain
residues bC79-R93 is a relatively slow event, it appears
conceivable that MHCII b-chain dynamics represent a major
step to free the system and provide an entropic contribution to
arrange the DM interface located in the a-chain. Communication
across the peptide-binding groove is confirmed by our simulation
of DR1-aT41A/CW, where a mutation in the a1 domain
indirectly influences the stability of the b1 domain a-helix
(Fig. 4a,g). A previously described hydrophobic network (b89F,
b153W, a48F)21, could function as a central allosteric
communication switch to translate dynamic modulation across
the binding groove.
Furthermore, we anticipate that our model can help to explain the
variability in DM susceptibility13,15,16,34 and peptide exchange rates
observed for DR and DQ alleles. Interestingly, the low DM
susceptibility observed for several DQ alleles15,16,35 that represent
risk factors for autoimmune disorders goes along with the
incorporation of residues with a higher helical propensity in the
region bG84-T90 and several additional hydrogen bonds lead to an
extension of the DR1 helical segment bR80-R90 to residue bR93.
Thus, these DQ alleles, namely DQ2 and DQ8, show a stabilization
of a structural segment, which we here prove to be a highly sensitive
element of conformational plasticity, and we argue that the dynamic
profile in these DQ alleles is modulated in a way that conformations
lying on-pathway for peptide exchange and DM binding are less
frequent, due to an increase in b-chain a-helix stability. On the other
hand, alleles DQ1 and DQ6, which are protective with regard to
T1D and which display enhanced DM susceptibility, show a more
open and thus less stable helical segment bG84-T90, a feature that
might be coupled to altered 310 helical flexibility for these variants.
We see our investigation as a contribution towards a unifying
concept of antigen presentation by class II molecules. Clearly, the
two major pathways described in this study are not strictly to
separate since most mutants or polymorphic variants will affect
both scenarios. On the one hand, changing the pocket occupation
or hydrogen bond network between MHCII and peptide will
directly impact intrinsic peptide release rates and increased
peptide dissociation will propagate to the flexible helical elements
required for DM binding. On the other hand, mutations more
remote from the binding groove such as the aT41A or bE87P
DR1 variants also investigated here are well suited to reveal the
more peptide-independent structural elements required for DM
editing and pave the way to understand the impact of certain
polymorphisms as discussed for the DQ alleles.
Furthermore, our model could help to explain the action of
small molecules on MHCII peptide exchange: several described
compounds appear to act at the N-terminal end of the peptide-
binding groove36–39, but direct experimental approaches to
confirm their binding sites have as yet remained fruitless.
We postulate that small molecule loading enhancers act on
low-populated conformational states described in this study.
Taking that idea further, drugs that induce adverse reactions
based on their interference with antigen presentation as shown
for Abacavir and MHCI40,41 might not only alter the presented
peptide repertoire by modifying pocket properties, but also by
influencing the exchange pathway.
The above presented concept of the relevance of the
conformational landscape of a ‘receptor’ molecule on down-
stream pathways might not only be applicable to the closely
related tapasin-catalysed peptide loading of MHC class I
molecules42–45 but is also known to other biological systems:
The energy landscape of G-protein coupled receptors that
strongly impacts activation pathways has been shown to
depend on the individual receptor/ligand complex46 and as
shown in this study, ligands might not act on the crystallizable
ground states but on low-populated excited states47. For example,
an order-to-disorder transition of two helical segments in the
rhodopsin effector Gai1 has been postulated and mutations that
affect the thermodynamic stability of this region were shown to
have a large effect on GDP release48. To determine the existence
and rate of formation of the implied rare conformations will be an
important step in a more universal understanding of G-protein
coupled receptor activation.
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In summary, we are able to rationalize key aspects of MHC
class II dependent antigen binding and exchange. Our work
thereby provides a blueprint for a thorough understanding of the
complex interplay between allelic variance and peptide repertoires
as they ultimately form and trigger T helper cell responses in
wanted and unwanted immune responses.
Methods
Expression and purification of soluble MHCII proteins. DRA*0101 and
DRB1*0101 (residues 1-192 and 1-198, respectively49) subunit-derived constructs
were generated by site-directed mutagenesis (SDM) using the standard
QuickChange protocol to introduce mutations. For crystallization of DR1-bN82A,
a CLIP106-120M107W peptide was genetically linked via a flexible tri-G4S-linker to the
N terminus of the b-subunit50,51.
HLA-DR proteins were produced as described previously49,52. To generate
pMHCII complexes, empty MHCII molecules were loaded with a 20-fold molar
excess of peptide in the presence of 2mM Ac-FR-NH2 dipeptide (loading
enhancer) for 48 h at 37 !C. Soluble monomeric pMHCII complexes and peptide-
free MHCIIs were finally obtained by applying the proteins and loading reactions
onto a size exclusion chromatography column and buffer exchanged to PBS, pH
5.8. DM was expressed and purified using the baculovirus-insect cell expression
system (pFastBacDual-Sf9) as previously described28.
Fluorescence polarization assays. Loading of 200 nM HA306-318-fluorescein
isothiocyanate (HA-FITC) on 1 mM DR1/peptide complexes was followed by
fluorescence polarization in the absence or presence of 250 nM DM (if not
stated otherwise). The reactions were set up in 40 ml in triplicates in PBS buffer,
pH 5.8 at 37 !C (Figs 1a and 4b). In order to resolve loading of DR1-bN82A/CW
experiments were performed at 25 !C (Fig. 3a). Peptide dissociation of 150 nM
DR/HA306-318-FITC complexes was monitored in the presence and absence of
20mM competitor peptide (HA306-318) and 150 nM DM in PB/Citrate buffer, pH
5.5 at 37 !C as previously described28. DFP values were calculated by subtracting
the measured fluorescence polarization of a protein-free reaction (HA-FITC only)
from the reaction containing the DR/peptide complexes.
Surface plasmon resonance. In all, 400–500 RU of biotinylated DM was
coupled to streptavidin (SAD 500, Xantec bioanalytics, Germany), as previously
described13. Experiments were carried out at 30 !C in 50mM citrate buffer,
150mM NaCl, pH 5.35, 0.06% C12E9 detergent, with a flow rate of 15 ml min" 1 in
a Biacore 3,000 device (GE Healthcare). Non-specific binding of the reference flow
cells was subtracted from the DM-coupled flow cells. DR1/peptide complexes were
injected for 300 s into DM-immobilized or control flow cells followed by 300 s
buffer injection and 450 s of 50mM HA peptide. The chip was regenerated by
injecting high-affinity peptides for the respective HLA-DR alleles in the flow cell at
concentrations ranging from 20 to 100mM.
Thermofluor assay. In order to determine the thermal stability, 0.2–0.5mgml" 1
monomeric pMHCII protein was mixed with 5# Sypro Orange (Life Technology).
While the temperature was increased for 2 !Cmin" 1, the emission was detected at
575 nm in lifetime after exciting the dye at 490 nm. Fluorescence intensity was
plotted versus the temperature and a sigmoidal function was fitted to determine the
midpoint temperature of the unfolding reaction (Tm). Stability measurements were
performed in PBS buffer, pH 5.8.
Nuclear magnetic resonance. NMR spectra were acquired on a Bruker AV700
MHz spectrometer equipped with a 5mm triple-resonance cryoprobe. Backbone
assignments of approximately 90% a- and around 80% b-chain resonances were
obtained for DR1/Cw and DR1-bN82A/CW by standard three-dimensional
experiments in combination with transferring assignments from DR1/C spectra20.
All NMR measurements were performed at 310K in PBS buffer pH 5.8
containing 10% D2O with 35–100 mM pMHCII. Spectra were processed with
Topspin (Bruker) and analysed with CcpNmr Analysis53.
MHCII complexes were partly deuterated a and fully deuterated b and
15Na- and/or 15Nb-labelled. DR1-bN82A samples used for assignments were
additionally 13C labelled. NOESY-HSQC spectra with 80ms mixing time were
acquired for 2H- 15Na/b-labelled DR1-bN82A/Cw with specific labelling of
1H-15N-Ala/Trp in the a and 1H-15N- Trp in the b-chain.
Chemical shift perturbation was calculated according to equation 1:
Dd1H15N ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
d1Hð Þ2 þ 0:15 ' d15Nð Þ2
q
ð1Þ
CcpNMR Analysis was used to determine the average spectral noise levels
from peak-free regions. For signal to noise level calculation peak-heights were
determined from 1H-15N-TROSY-HSQC spectra of 50 mM 15N b-labelled DR1/Cw
(144 scans, noise level 2,450), 50 mMDR1-bN82A/Cw (144 scans, noise level 2,594),
60mM 15N a-labelled DR1/Cw (144 scans, noise level of 5,093) and 35 mM 15N
a-labelled DR1/Cw (340 scans to account for the difference in protein
concentration, noise level of 3,997) measured at 37 !C for Fig. 2e.
H/D exchange. Protected hydrogen atoms can exchange against deuterium in a
transient energy state of a protein region, typically involving H-bond breakage 54.
For native state proteins at pH values below 10, the EX2 limit can be used to obtain
the equilibrium constant for the exchange according to equation 2:
Kex ¼ kobskint ¼ P
" 1 ð2Þ
where kobs is the observed exchange rate, kint the intrinsic exchange, which
has to be experimentally determined (or derived from the Sphere databases,
http://landing.foxchase.org/research/labs/roder/sphere/), and P" 1 is the amide
protection factor. Based on the knowledge of Kex, the energy difference between the
open and closed state is calculated using the following equation:
DGop=cl ¼ "R ' T ' lnKex ð3Þ
where DGop/cl refers to the energy difference between the open and the closed state,
R to the universal gas constant (0.00831462 kJ K" 1mol" 1) and T to the absolute
temperature in Kelvin.
Partly deuterated a and fully deuterated b 15Na- and/or 15Nb-labelled DR1/CW
complexes were concentrated to 80–100 mM in PBS buffer, pH 5.7, 10% D2O,
0.02% NaN3. Reference HSQC spectra were acquired with 1,024# 96 complex data
points and 16 scans at 37 !C. Afterwards, these DR1/peptide complexes were shock
frozen and lyophilized overnight. Immediately after re-solubilization in 100% D2O
a set of 90 HSQC experiments were acquired with a measurement time ofB35min
per HSQC. At least 20 data points of the HSQC data set was used to plot S/N ratios
of NH peaks against the experiment time. NH groups exchanging to an
undetectable level within the dead time of the HSQC measurement (B35min)
were considered to have half-lives (t1/2) ofo15min, while NH groups not showing
adequate signal decay after 60 h were classified as highly stable, with a t1/2
44,000min and peaks with overlapping maxima were mostly excluded from the
analysis. For peaks, which showed a clear decay within the experiment time
(B60 h), an exponential decay function of first order was fitted to the data
according to the EX2-limit55. Kex" 1 was obtained by normalizing the observed
exchange rates for the intrinsic exchange rates (an average for the intrinsic rates
was calculated with respect to the i±1 position; http://landing.foxchase.org/
research/labs/roder/sphere/).
All together, 99 DR1/CW and 124 DR1-bN82A/CW residues displayed t1/2 of
o15min, 87 DR1/CW and 72 DR1-bN82A/CW residues displayed t1/244,000min,
85 DR1/CW and 64 DR1-bN82A/CW residues could be fitted.
Crystallization and structure determination. Both proteins were crystallized
using commercial sparse matrix screens. DR1 was purified and refolded from
Escherichia coli. To obtain DR1/CW the peptide was loaded a posteriori using a
10- to 20-fold molar excess of peptide in the presence of 1mM AdEtOH37 or 2mM
Ac-FR-NH2 (ref. 39) as molecular loading enhancer overnight at 37 !C. Unbound
peptide was removed by size exclusion chromatography using a Superdex 200
column (GE Healthcare, USA) into 20mM MES, 50mM NaCl, pH 6.4. The
complex was concentrated to 10mgml" 1 and subjected to crystallization by
vapour diffusion in sitting drops. Diffraction-quality crystals grew within a few
days in 0.2M K/Na-tartrate, 20% (w/v) PEG3350, 0.1M BisTrisPropane, pH 8.5.
For DR1-bN82A/CW, the protein was purified and refolded from E. coli and gel
filtrated using a Superdex 200 column equilibrated in 20mM MES, 50mM NaCl,
pH 6.4. Protein was concentrated and mixed with an equimolar amount of DM
purified from S2 cells in the same buffer. The final protein concentration was
10mgml" 1. Crystals were grown by vapour diffusion in sitting drops in 0.2M Na
nitrate, 20% (w/v) PEG 3350, 0.1M BisTrisPropane, pH 7.5.
In both cases, crystals were harvested and flash frozen in the crystallization
condition supplemented with 20% glycerol. Data from these crystals were collected
at beamline 14.1 at Helmholtz-Zentrum Berlin.
In both cases, data sets were processed using the XDS package56. Initial phases
were obtained by molecular replacement using the program PHASER57 using
HLA-DR1 (PDB 2G9H) as a search model with the coordinates of the peptide
removed. The final models were built using iterative rounds of refinement with the
Phenix program package58 interspersed with manual model building in COOT59.
Despite the presence of equimolar amounts of DM in the crystallization
conditions for the crystals of DR1-bN82A/CW, no DM could be identified in the
electron-density. Both structures were deposited at the Protein Data Bank with
accession codes 4X5W and 4X5X.
MD set-up. The DR1/C (3PDO) and DR1/CW (4X5W) crystal structures were
analysed. pKa values of titratable residues for each structure were estimated with
the program propKa60. Together with the gromacs program pdb2gmx61 and
previous MD simulation studies performed on MHCII (ref. 12), protonation states
were assigned for MHCII-physiological pH¼ 5.8 that are consistent among these
structures (fully-protonated His: a5/33/177, b16/81/111; e-prot. His: a143/149/167,
b112/177, prot. Asp: a25/29, prot. Glu: a11/21), together with disulphide bridges
we introduced (aC107-aC163, b15-b79, b117-b173). In DR1, unresolved atom
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coordinates of aL105-F112, bQ107-H112 were modelled by superposition with
corresponding templates taken from 3PDO. Standard (charged) termini were used
for chains a and b, whereas CLIP’s N and C terminus were acetylated and
amidated, respectively. The corresponding mutations in the starting structures of
DR1/CW and DR1-bN82A/CW were modelled atomically clash-free by substituting
the bAsn82 (CLIP Met107) side-chain with the one of Ala (Trp) resulting in four
different starting structures. The starting structures for 162 DR1-bT41A/CW
simulations were generated from the MSM of the DR1/CW simulations by
uniformly sampling in the kmeans-clustered (k¼ 6E sqrt(no. of microstates in the
largest connected MSM set)) space of the first three MSM eigenvectors. Each
structure was aligned onto its principal axes and solvated with a 150mM l" 1
NaCl using VMD58. The resulting simulation boxes were about 70# 80# 120Å
contained 67,000 atoms, including 20,000 water molecules.
MD simulations. Simulations were run using ACEMD62 with the ff99SB63 Amber
force-field, an integration time-step of 4 fs and a hydrogen mass scaling factor of 4,
a 1–4 scaling factor of 5/6, orthorhombic periodic boundary conditions and
Particle Mesh Ewald electrostatics with 1 Å grid spacing, a 9Å cutoff, switching at
7.5 Å, scale1–4 exclusion, full electrostatic frequency of 2 steps, fixed bonded
interactions between heavy atoms and hydrogens (‘rigidbonds all’), and Langevin
dynamics. In the beginning of the MD simulations, three replicates of each of the
four starting structures were subjected to 5,000 steps of minimization, followed by
8ns isothermal-isobaric ensemble (NPT) equilibration with with 1 ps" 1 Langevin
damping, 1 atm Berendsen pressure and 800 fs relaxation time, and with harmonic,
positional restraints on all protein heavy atoms (initial force constant:
5 kcalmol" 1 Å" 2). For the first 4ns in steps of 0.1 ns, these restraints were
gradually reduced to zero, while the simulation temperature was gradually
increased from 10K to 310K. For the remaining MD simulations, the pressure
control was turned off (NVT- canonical ensemble), and the Langevin damping was
set to 0.1 ps" 1. Each of these remaining simulations, that is, of the six replicates for
each DR1/CW and DR1-bN82A/CW, we performed for about 1 ms. Each final
restart point of these simulations was then replicated again (27 times), and
simulated on the Titan supercomputer for another 550 ns each. Each of the 162
DR1-bN82A/CW simulations was run on an in-house graphics-processing unit
(GPU) cluster for 200–1,100 ns. The resulting MD simulation data set of 486
individual simulations with 275 ms total aggregated simulation time was then used
for analysis.
Throughout all our MD simulations, we harmonically restrained the center of
mass and the inertia tensor’s off-diagonal elements of pMHCII’s heavy atoms to
zero. We implemented these restraints as an ACEMD plugin, which is available
upon request. This strategy allowed us to perform our MD simulations with the
periodic boundary conditions more efficiently, as the principle components of this
intertia tensor had been aligned in the starting structures (see ‘MD set-up’).
This gain in efficiency (B50% speed-up for pMHCII) is due to the fact that an
additional box size (and thus additional water molecules) is not necessary to
accommodate for the rotational tumbling of pMHCII under periodic boundary
conditions, as has been studied previously64,65. For pMHCII, the force constant
values of these restraints (2 kcalmol" 1 Å" 2 and 2 kcalmol" 1 Å" 4, respectively)
were carefully chosen, so that with a minimal bias, the minimal distances between
pMHCII and each of its periodic images would not fluctuate on average over all
three box dimensions by more than 0.8 Å during short MD test simulations
(o50 ns). In the course of our MD simulations, these minimal distances were
closely monitored not to be smaller than two times 9Å, the electrostatic cutoff.
Markov state modelling. MSMs24,47,66–68 were constructed with pyEMMA
(www.pyemma.org)26 to arrive at a systematic analysis of the large amounts of
simulation data. The data of DR1/CW as well as the DR1-bN82A/CW, and
DR1-aT41A/CW mutants were transformed and discretized in the same way in
order to arrive at models at which the effect of the mutant can be consistently
compared: In particular, the MSMs for DR1/CW and DR1-bN82A/CW were
computed from the combined discretized simulation set of DR1/CW and
DR1-bN82A/CW, whereas the MSM for DR1-aT41A/CW was determined from
the combined discretized simulation set of DR1/CW, DR1-bN82A/CW and
DR1-aT41A/CW. To this end, all pairwise Ca-coordinates of residues within 15Å
of bN82 in a simulated 3PDO conformation (that is, aH5-aA10, aM23-aD27,
aE30-aF32, aF48-aE55 (not aR50), bR13-bL27 (not bN19), bR71-bR93
(not bR72, bn82)) were used as input coordinates to a time-lagged independent
component analysis69,70. After the time-lagged independent component analysis
transform, the three most important reaction coordinates were partitioned to
100 discrete states using k-means clustering. The simulations were assigned to this
discrete state space and a reversible Markov model was estimated using the
algorithm described in ref. 67. Based on implied timescales calculations71, a lag
time of 200 ns was selected (Supplementary Fig. 10, left panels). The resulting
Markov models were validated using a Chapman–Kolmogorov Test67,72
(Supplementary Fig. 10, right panels), and coarse-grained into three metastable
states using PCCAþ þ 73 (Figs 1d and 3g) to represent metastable conformational
transitions on the microsecond scale. Molecular graphics and movies were
generated with the program PyMol74.
Pairwise interaction analysis. Pairwise interactions and their significant
differences between pairs of metastable states were detected with a modification of
the system-wide Pairwise Interaction Analyser75,76: For every simulation frame
assigned to a metastable conformation, a pairwise interaction between two sets of
heavy atoms (for example, the heavy side-chain or backbone atoms a residue) is
inferred to exist, if the two sets fulfill certain geometric criteria evaluated by the
program HBPLUS77, or the program VMD78 (using a distance criterion provided
in ref. 79). For a bootstrapped sample of 100 frames from an metastable state, the
list of pairwise interactions were then combined into relative interaction
frequencies, and the averages and standard deviations of these frequencies is
computed for 50 of such bootstrapped samples. For each bootstrapped metastable
state sample, entire trajectories are resampled with fixed k-means microstate
definition and microstate-to-metastable state mappings and updated Markov
model.
Data availability. The crystal structures of DR1/CW (4X5W) and
DR1-bN82A/CW (4X5X) have been deposited with the Protein Data Bank with
accession codes 4X5W and 4X5X, respectively. The data that support the findings
of this study are available from the corresponding authors upon request.
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